Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2007

01-04-2007 | Original Article

Modafinil’s Use in Combating Interferon-Induced Fatigue

Authors: Kari A. Martin, Lois E. Krahn, Vijayan Balan, Marianne J. Rosati

Published in: Digestive Diseases and Sciences | Issue 4/2007

Login to get access

Abstract

Interferon (IFN) is an effective agent in the treatment of chronic viral hepatitis C. A variety of adverse neuropsychiatric effects including anxiety, depression, delirium, psychoses, and mania complicates its usage. IFN-α-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]. Our results show that depression-specific symptoms peak at 12 weeks of IFN therapy and respond well to serotoninergic antidepressants [2]. We conclude that neurovegetative symptoms are relatively treatment refractory to antidepressants, occur early in the course of treatment, and tend to persist for the duration of therapy [1].
Literature
1.
go back to reference Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2):105–123PubMedCrossRef Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19(2):105–123PubMedCrossRef
2.
go back to reference Hauser P (2004) Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 33(Suppl 1):S35–S50PubMed Hauser P (2004) Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 33(Suppl 1):S35–S50PubMed
3.
go back to reference Geppert CM, Dettmer E, Jakiche A (2005) Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics 46(5):392–401PubMedCrossRef Geppert CM, Dettmer E, Jakiche A (2005) Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics 46(5):392–401PubMedCrossRef
4.
go back to reference Poynard T, Cacoub P, Ratziu V, et al. (2002) Fatigue in patients with chronic hepatitis C. J Viral Hepat 9(4):295–303PubMedCrossRef Poynard T, Cacoub P, Ratziu V, et al. (2002) Fatigue in patients with chronic hepatitis C. J Viral Hepat 9(4):295–303PubMedCrossRef
5.
go back to reference Sarhill N, Walsh D, Nelson, et al. (2001) Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 18(3):187–192PubMedCrossRef Sarhill N, Walsh D, Nelson, et al. (2001) Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 18(3):187–192PubMedCrossRef
6.
go back to reference Krupp LB (2003) Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs 17(4):225–234PubMedCrossRef Krupp LB (2003) Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs 17(4):225–234PubMedCrossRef
7.
go back to reference Rammohan KW, Rosenberg JH, Lynn DJ, et al. (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72(2):179–183PubMedCrossRef Rammohan KW, Rosenberg JH, Lynn DJ, et al. (2002) Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72(2):179–183PubMedCrossRef
8.
go back to reference Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21(1):9–14PubMed Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 21(1):9–14PubMed
9.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123PubMed Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123PubMed
10.
go back to reference Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63(10):1908–1911PubMed Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 63(10):1908–1911PubMed
11.
go back to reference Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287– 293PubMedCrossRef Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18(3):287– 293PubMedCrossRef
12.
go back to reference Robertson Jr P, Hellriegel ET (2003) Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42(2):123– 137CrossRef Robertson Jr P, Hellriegel ET (2003) Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42(2):123– 137CrossRef
Metadata
Title
Modafinil’s Use in Combating Interferon-Induced Fatigue
Authors
Kari A. Martin
Lois E. Krahn
Vijayan Balan
Marianne J. Rosati
Publication date
01-04-2007
Published in
Digestive Diseases and Sciences / Issue 4/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9519-0

Other articles of this Issue 4/2007

Digestive Diseases and Sciences 4/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine